» Articles » PMID: 31346036

Abrogation of FBW7α-dependent P53 Degradation Enhances P53's Function As a Tumor Suppressor

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2019 Jul 27
PMID 31346036
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The gene encoding the tumor suppressor p53 is mutated in most cancers. p53 expression is known to be tightly controlled by several E3 ligases. Here, we show that F-box and WD repeat domain-containing 7α (FBW7α), the substrate-recognition component of the SCF multiprotein E3 ligase complex, targets both WT and tumor-derived mutants of p53 for proteasomal degradation in multiple human cancer cell lines (HCT116 and U2OS). We found that lack of FBW7α stabilizes p53 levels, thereby increasing its half-life. p53 ubiquitylation and subsequent degradation require the F-box and the C-terminal WD40 repeats in FBW7α. The polyubiquitylation of p53 occurred via Lys-48 linkage and involved phosphorylation on p53 at Ser-33 and Ser-37 by glycogen synthase kinase 3β (GSK3β) and DNA-dependent protein kinase (DNA-PK), respectively. These phosphorylation events created a phosphodegron that enhanced p53 binding to FBW7α, allowing for the attachment of polyubiquitin moieties at Lys-132 in p53. FBW7α-dependent p53 polyubiquitylation apparently occurred during and immediately after DNA double-strand breaks induced by either doxorubicin or ionizing radiation. Accordingly, in cells lacking FBW7α, p53 induction was enhanced after DNA damage. Phosphodegron-mediated polyubiquitylation of p53 on Lys-132 had functional consequences, with cells in which FBW7α-mediated p53 degradation was abrogated exhibiting enhancement of their tumorigenic potential. We conclude that p53, which previously has been reported to transactivate FBW7, is also targeted by the same E3 ligase for degradation, suggesting the presence of a regulatory feedback loop that controls p53 levels and functions during DNA damage.

Citing Articles

Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression.

Indeglia A, Murphy M Crit Rev Biochem Mol Biol. 2024; 59(1-2):128-138.

PMID: 38661126 PMC: 11209770. DOI: 10.1080/10409238.2024.2344465.


Isoform alterations in the ubiquitination machinery impacting gastrointestinal malignancies.

Kasturirangan S, Nancarrow D, Shah A, Lagisetty K, Lawrence T, Beer D Cell Death Dis. 2024; 15(3):194.

PMID: 38453895 PMC: 10920915. DOI: 10.1038/s41419-024-06575-z.


FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies.

Wang W, Jiang K, Liu X, Li J, Zhou W, Wang C Front Pharmacol. 2023; 14:1278056.

PMID: 38027013 PMC: 10680170. DOI: 10.3389/fphar.2023.1278056.


Biallelic FBXW7 knockout induces AKAP8-mediated DNA damage in neighbouring wildtype cells.

Chan D, Mandal A, Hester S, Yu Z, Higgins G, Kessler B Cell Death Discov. 2023; 9(1):200.

PMID: 37386001 PMC: 10310709. DOI: 10.1038/s41420-023-01494-y.


Ubiquitination Links DNA Damage and Repair Signaling to Cancer Metabolism.

Koo S, Park E, Noh H, Jo S, Ko B, Shin H Int J Mol Sci. 2023; 24(9).

PMID: 37176148 PMC: 10179089. DOI: 10.3390/ijms24098441.


References
1.
Wong K, DeDecker B, Freund S, Proctor M, Bycroft M, Fersht A . Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci U S A. 1999; 96(15):8438-42. PMC: 17534. DOI: 10.1073/pnas.96.15.8438. View

2.
Rodriguez M, Desterro J, Lain S, Lane D, Hay R . Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol. 2000; 20(22):8458-67. PMC: 102152. DOI: 10.1128/MCB.20.22.8458-8467.2000. View

3.
Turenne G, Price B . Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity. BMC Cell Biol. 2001; 2:12. PMC: 35361. DOI: 10.1186/1471-2121-2-12. View

4.
Bunz F, Fauth C, Speicher M, Dutriaux A, Sedivy J, Kinzler K . Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res. 2002; 62(4):1129-33. View

5.
Spruck C, Strohmaier H, Sangfelt O, Muller H, Hubalek M, Muller-Holzner E . hCDC4 gene mutations in endometrial cancer. Cancer Res. 2002; 62(16):4535-9. View